uniqure.com - QURE Total Stockholders' Equity
uniQure N.V. (QURE) attracts leading geneticists through its powerful R&D potential and stock option system. The company is currently transitioning to the commercialization of breakthrough hemophilia treatments, as confirmed by this price action chart, where the indicator stands at 0.32. The business relies on its own full-cycle production, allowing for total control over the manufacture of innovative drugs and the maintenance of leadership within the gene therapy sector.
%20Book%20Capitalization&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_QURE_-_uniQure-N.V._-_Book-Capitalization "QURE (uniQure Corp) Accounting Capitalization history from 07/04/2022 to 10/30/2026 | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for uniQure (QURE)
The business of uniQure N.V. (QURE) is based on the commercialization of gene therapy and revenues from the drug HEMGENIX. This indicator reflects the net asset value, representing the difference between all liabilities and the company's total resources. By analyzing the current book value of equity, an investor sees the actual foundation of the business without market speculation. This trend captures the efficiency of capital accumulation for the development of new products. Such securities are classified as high-risk assets with long-term potential.